TRAF3 and B-cell neoplasm: However, further studies (using genetic means or more specific PKCδ activators) are required to establish the possibility of activating PKCδ nuclear translocation as a therapeutic avenue for B cell neoplasms with TRAF3 deletions or inactivating mutations.